Skip to main content
Premium Trial:

Request an Annual Quote

Cue Health, Google Cloud Partner to Track Respiratory Viral Variants

NEW YORK – Cue Health announced on Wednesday that it is collaborating with Google Cloud to add respiratory viral variant sequencing and tracking to its Cue Integrated Care platform.

San Diego-based Cue said it will build Google Cloud's artificial intelligence, machine learning, analytics, and privacy and security tools into its platform, which includes its Cue Health Monitoring System and rapid molecular COVID-19 test.

The assay received Emergency Use Authorization from the US Food and Drug Administration for home and over-the-counter use in March.

Cue said it will integrate the cloud-connected COVID-19 information in its platform with sequencing data and artificial intelligence tools which "will equip public health officials and researchers with critical, real-time information about variant types … and predictive capabilities to help identify and curb emerging threats." 

The integration is also intended to help in future outbreaks of infectious diseases and pandemics beyond COVID-19, including influenza and respiratory syncytial virus. Cue is currently developing tests for both influenza and RSV, it added.

"Together with Google Cloud, we can combine immediate and connected lab-quality diagnostics with the power of genome sequencing and AI-enabled predictive capabilities to develop a new kind of tool for public health," Cue cofounder and CEO Ayub Khattak said in a statement. 

"Through this collaboration, we’re bringing Google Cloud’s expertise in data analytics, AI, and [machine learning] to Cue, helping them to reach even more communities and have an even greater impact in helping to identify, predict, and mitigate the spread of infectious diseases," Janet Kennedy, VP of North America Regions at Google Cloud, added in a statement.

Last month, Cue filed documents with the US Securities and Exchange Commission to go public, seeking up to $100 million in a proposed initial public offering.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.